In Tables 2–4 and Table 1 in Appendix, we compared the efficacy/safety of tildrakizumab in treating psoriasis with clinical trials conducted using other biologic agents: IL-23 inhibitors [i.e., guselkumab (72, 74), risankizumab (79), mirikizumab (82)], IL-23/12p40 inhibitor [i.e., ustekinumab (51, 52)], IL-17/IL-17 receptor inhibitors [i.e., secukinumab (135), ixekizumab (123), brodalumab (136), and bimekizumab (137)], and TNF-α inhibitors [i.e., etanercept, infliximab (138), adalimumab (139), certolizumab pegol (140), and golimumab (141)]. The gene discussed is IL37; the disease is psoriasis.